SLC5A2 and hydrops fetalis: As shown in eFigure 5 in the Supplement, ASIs plus β-blockers plus SGLT2 inhibitors were associated with a significant reduction in the risk of HF hospitalization compared with ASIs (HR, 0.57 [95% CrI, 0.30-0.98]), β-blockers (HR, 0.60 [95% CrI, 0.48-0.75]), ASIs plus β-blockers (HR, 0.71 [95% CrI, 0.60-0.83]), and ARNIs plus β-blockers (HR, 0.79 [95% CrI, 0.64-0.97]).